A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia

Status Terminated

Clinical Trial Summary

This study evaluates the use of tranexamic acid (TXA) in addition to standard therapy in children receiving chemotherapy or blood and/or marrow transplantation to decrease the risk of bleeding. Half of participants will receive tranexamic acid and half of participants will receive placebo.

Clinical Trial Description

The purpose of this study is to conduct a prospective, randomized, blinded, placebo controlled trial to evaluate the safety and feasibility of the addition of antifibrinolytic therapy with tranexamic acid to the standard care in patients who are thrombocytopenic due to primary bone marrow disorders or chemotherapy, immunotherapy and/or radiation therapy in order to prevent bleeding. The results of this study will change practice by providing evidence as to whether or not TXA is effective and safe treatment when used as an adjunct to platelet transfusion therapy in the thrombocytopenic patient. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03806556
Study type	Interventional
Source	University of Pittsburgh
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	April 22, 2019
Completion date	August 25, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04003220` - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Completed	`NCT02948283` - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia	Phase 1
Recruiting	`NCT03633019` - High-dose Use of rhTPO in CIT Patients	Phase 4
Recruiting	`NCT06087198` - Clinical Performance Evaluation of T-TAS®01 HD Chip
Recruiting	`NCT03605511` - TTP and aHUS in Complicated Pregnancies
Active, not recruiting	`NCT03688191` - Study of Sirolimus in CTD-TP in China	Phase 4
Completed	`NCT02845609` - Efficacy of Sialic Acid GNE Related Thrombocytopenia	Phase 2
Recruiting	`NCT02241031` - Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia	Phase 2/Phase 3
Recruiting	`NCT02244658` - Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia	Phase 3
Unknown status	`NCT01196884` - Immune Thrombocytopenia (ITP) Immune-Genetic Assessment
Completed	`NCT01356576` - Effect of Hemodialysis Membranes on Platelet Count	N/A
Terminated	`NCT01368211` - Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)	Phase 2/Phase 3
Completed	`NCT00039858` - Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin	Phase 4
Completed	`NCT00787241` - Platelet Count Trends in Pre-eclamptic Parturients	N/A
Completed	`NCT00001533` - Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine	Phase 1
Not yet recruiting	`NCT06036966` - The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients	Phase 2
Completed	`NCT01791101` - Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.	Phase 2
Recruiting	`NCT06053021` - Antiplatelet Therapy for AIS Patients With Thrombocytopenia	N/A
Recruiting	`NCT03701217` - Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML	Phase 2/Phase 3
Not yet recruiting	`NCT05958511` - Assessment of Risk Factors and Outcome of Thrombocytopenia in ICU Patients